The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease
who are having trouble with their thinking or behavior. In particular, this study is trying
to find out the best treatment for people who have hallucinations (seeing or hearing things
that aren't there), delusions (false beliefs), or agitation. The design of the trial helps to
increase the chance that participants in the study receive a medication that helps them. The
study uses three medications known as atypical antipsychotics (olanzapine, quetiapine,
risperidone), which are the newest medications that are currently available for treating
these problems. Participants may also receive an antidepressant (citalopram). The trial lasts
for 36 weeks. Participants are given a thorough evaluation at no cost to ensure that this
study is appropriate. In addition, the caregiver, family member, or friend who comes with the
participant will be offered an educational program about Alzheimer's disease.